Project funded in 2005 - Strand 1: Health Information

IMCA II - Indicators for Monitoring COPD and Asthma in the EU

Description

Action
Improving information and knowledge for the development of public health

Area of activity
Developing mechanisms for the reporting and analysis of health issues and producing public health reports

Summary
Asthma and COPD are major chronic disease that have an important impact on quality of life of individuals suffering the disease and also have important consequences into social and health care cost. The information available today either to prevent risk factors or to improve clinical management and outcomes is still very limited. The aim of this proposal is to extend the work on indicators already carried out by the IMCA I project by collecting or using already available data and producing reports/papers on all groups of indicators recommended by the project (mortality, prevalence, risk factors, clinical management/health services and outcomes). We will collect routine data on mortality and hospital discharges to estimate the indicators defined by the IMCA I project (for a period of ten years) for all countries involved in the project and to analyze geographical variations and time trends on these indicators. We will also collect data on health care, human resources and health care utilization costs to estimate the indicators defined by the IMCA I project. Available data from completed European-wide research projects (ECRHS and ISAAC) will be used to describe the most relevant indicators. Available data from completed European-wide research projects (ECRHS and ISAAC) will be used to describe the most relevant indicators.

The project also aim extend the work of IMCA I project by developing a module of COPD and asthma to be incorporated to health examination surveys and testing its feasibility and pilot performance in four selected small a large sample of geographical areas of Spain, Italy, Sweden and Germany. in Europe. We will explore the use of a group of essential measurements of respiratory health and morbidity to be introduced in future HES using innovative technological methods (sensors) to carry out measurements, validate and transmit the data (fieldwork online) and the use of a Telemedicine Network (GBT-UPM) to provide training and support online to the fieldworkers. This technology that will be used has been developed by MOTOROLAHEALTH. A new questionnaire "module" based in previously validated questionnaires by which the information required to estimate the IMCA I indicators (recommended to be collected by survey) can be obtained will be developed. The project will explore the feasibility of taking a blood sample at home in the context of a HES to measure the relevant indicators on allergy (IgE and specific IgE), obtain DNA samplesobtention and other ad hoc determinations.

More info...

Financing

Leader organisation
Fundació IMIM
C/ Dr Aiguader 88
08003 Barcelona
SPAIN
Contact Person
Enric DURAN
Tel: +34932211009
Fax: +34932213237
E-mail: e.duran@imim.es
 

Associated beneficiaries
  • Prestacions d’Assistència Mèdica SL - established in Spain
  • Hospital Clínic i Provincial de Barcelona- established in Spain
  • Medizinische Universitat Wien- established in Austria
  • Hvidovre Hospital- established in Denmark
  • Kansanterveyslaitos - National Public Health Institute - established in Finland
  • Université de la Méditerranée Aix Marseille II - established in France
  • Universitatsklinikum Ulm - established in Germany
  • PNOE Asthma Research Foundation - established in Greece
  • University of Crete - established in Greece
  • Research Institute for a Tobacco Free Society (RIFTRS) - established in Ireland
  • Consiglio Nazionale delle Ricerche, Institute of Clinical Physiology - established in Italy
  • Azienda Sanitaria Locale Roma, Dipartimento d’Epidemiologia - established in Italy
  • Centre Hospitalier de Luxembourg - established in Luxembourg
  • Rijksinstituut voor Volksgezondheid en Milieu (RIVM) - established in the Netherlands
  • Sociedade Portuguesa de Alergologia e Imunologia Clinica - established in Portugal
  • Uppsala Universitet - established in Sweden
  • Imperial College of Science, Technology and Medicine - established in the United Kingdom
  • Innovest AS - established in Norway
  • Association Asthma - established in Bulgaria
  • Cyprus International Institute for the Environmental and Public Health in Association with Harvard School of Public Health - established in Cyprus
  • Czech Initiative for Asthma - established in the Czech Republic
  • Sihtasutus Tartu Ulikooli Kliinikum - Tartu University Hospital - established in Estonia
  • Fodor Jozsef National Centre For Public Health - established in Hungary
  • National Tuberculosis and Long Diseases Research Institute (IGICHP) - established in Poland
  • Landspitali University Hospital - established in Iceland
  • University Clinic of Respiratory and Allergic Diseases - established in Slovenia
  • Universitatea de Medicina si Farmacie Iuliu Hatieganu - University of Medicine and Pharmacy - established in Romania
  • Health Department of Catalonia- established in Spain
Starting date and duration of project
- 15/12/2006
- 36 months

Total cost
2.729.034 €

Subsidy from the Commission
1.637.420 €

Outcomes

Results to be achieved
Work package 1: Coordination of the project
  1. Set up a structure for project organization and management.
  2. Ensure communication and interaction with other EU projects.
  3. Facilitate communication with international organizations (IO) and scientific societies (SC).
  4. Provide a platform (internal and external) to facilitate communication and coordination.

Work package 2: Dissemination of the results
  1. To disseminate the results already obtained by the first IMCA project.
  2. To disseminate the results and the technological methodology of epidemiological investigation obtained by the feasibility study within the proposed IMCA II project.
  3. To promote awareness of the importance of the epidemiological monitoring of COPD and asthma among health professional, health educational authorities and general population.

Work package 3: Evaluation of the project
  1. To monitor project development by using qualitative and quantitative indicators by monitoring milestones and deliverables.
  2. To determine to what extent the objectives have been accomplished on time.
  3. To establish the impact of the project on different target audiences.
  4. To support and help the project Steering Committee to make strategic decisions

Work package 4: Indicators from routine databases
  1. To collect the routine data on mortality and hospital discharges necessary to estimate the indicators defined by the IMCA project for all countries involved in the project.
  2. To collect data on health care, human resources and health care utilization costs to estimate the indicators defined by the IMCA project for all countries involved in the project.
  3. To analyze geographical variations and time trends on mortality and hospital discharges at national level for all countries involved in the project.

Work package 5: Indicators from international research studies
  1. Describe Health Indicators for Asthma and COPD as defined in IMCA I Project Report using available data from completed European-wide research projects (ECRHS, ISAAC; AIRE).
  2. Identify public health priorities at national level suggested by these indicators.
  3. Determine whether public health priorities would be altered by additional information on prevalence of relevant genetic polymorphisms within European populations or by knowledge of gene-environment interactions.

Work package 6: Pilot study: respiratory measurements in HES
  1. To develop a questionnaire (module) and its software to be used in future HES using innovative methods of data collection and transmission.
  2. To recommend the essential measurements (spirometry, pulsioximetry, weight, height, exhaled NO, and glucose) and its technological characteristics to be included in future HES useful for the diagnosis of COPD and asthma.
  3. To carry out a pilot and feasibility study on innovative methods (sensors) to perform the essential measurements recommended using MOTOROLAHEALTH technology in four small European geographical areas.
  4. To explore the feasibility to take a blood samples to measure total IgE, specific IgE and to create a DNA databank in future HES.

More info

Statement of project aim(s) and objectives
General objectives
The first aim of the IMCA II is to extend the work on indicators already carried out by the IMCA I project by collecting or using already available data and producing reports/papers on all groups of indicators recommended by the project (mortality, prevalence, risk factors, clinical management/health services and outcomes). This work will qualitatively and quantitatively improve the current level of information on COPD and asthma in the EU and will provide relevant information, based on the scientific evidence, necessary for clinical and health care policy decision making at all levels of health care administration.

The second aim is to extend the work of IMCA I project by developing a module of COPD and asthma to be incorporated to health examination surveys and testing its feasibility and pilot performance in four selected small geographical areas of Spain, Italy, Sweden and Germany. This work will provide new instruments to collect all relevant information required to estimate all indicators recommended by the IMCA I project. This new module on respiratory diseases will solve the methodological problems indentified by the IMCA project in the past and current instruments and measurements used in most studies. and testing its feasibility and pilot performance in a large sample of geographical areas in Europe. This work will provide new instruments to collect all relevant information required to estimate all indicators recommended by the IMCA I project. This new module on respiratory diseases will solve the methodological problems identified by the IMCA project in the past and current instruments and measurements used in most studies.

Specific objectives
  1. To extend the work on indicators already carried out by the IMCA I project by collecting or using already available data and producing reports/papers on all groups of indicators recommended by the project (mortality, prevalence, risk factors, clinical management/health services and outcomes).
  2. To collect routine data on mortality and hospital discharges to estimate the indicators defined by the IMCA I project (for a period of ten years) for all countries involved in the project and to analyze geographical variations and time trends on these indicators.
  3. To collect data on health care, human resources and health care utilization costs to estimate the indicators defined by the IMCA I project.
  4. To describe and analyze health indicators for COPD and asthma as defined in the IMCA I project using available data from completed European-wide research projects (ECRHS and ISAAC).
  5. To extend the work of IMCA I project by developing a module of COPD and asthma to be incorporated to health examination surveys and testing its feasibility and pilot performance in four selected small geographical areas of Spain, Italy, Sweden and Germany.
  6. To explore the use of a group of essential measurements of respiratory health and morbidity to be introduced in future HES using innovative technological methods (sensors) to carry out measurements, validate and transfer the data (fieldwork online) and the use of a Telemedicine Network (GBT-UPM) to provide training and support online to the fieldworkers. This technology that will be used has been developed by MOTOROLAHEALTH.
  7. To design a new questionnaire "module" based in previously validated questionnaires by which the information required to estimate the IMCA I indicators (recommended to be collected by survey)can be obtained.
  8. To explore the feasibility of taking a blood sample at home in the context of a HES to measure the relevant indicators on allergy (IgE and specific IgE) obtain DNA samples and other ad hoc determinations for specific polymorfisms.

Methods
The work to be carried out by the IMCA II project to achieve the two general and all specific objectives involve the use of a quite large number of methodologies described in the "Description of Work" of each specific work package. The IMCA group is integrated by a large multidisciplinary team with a large experience in the field of respiratory diseases and in implementing large international studies. The IMCA group will guarantee that all tasks described in all WP's are developed using the most appropriate methodologies to deliver the project outputs at the highest standard possible from the scientific and public health point of view. Perhaps, with regard to the methodological point of view, we should emphasize the innovative character of the methods to perform biological measurements, data collection and transmission using the new technology developed by MOTOROLAHEALTH.